Apelin as a Candidate for Hypertension Management; a Systematic Review and Meta-Analysis on Animal Studies
学术急诊医学档案,
卷 10 编号 1 (2022),
1 十月 2022
,
第 e90 页
https://doi.org/10.22037/aaem.v10i1.1704
摘要
Introduction: Hypertension is a medical emergency that requires immediate medical attention. Recent studies have suggested that peripheral injection of Apelin may lower blood pressure. However, there is no comprehensive conclusion on the role of Apelin in treatment of hypertension. The aim of this systematic review was to evaluate the effects of Apelin on blood pressure in animal studies.
Method: Extensive search and data gathering were conducted using keywords related to blood pressure and Apelin on Medline, Embase, Scopus, and Web of Science databases at the end of July 2022. Two researchers screened and summarized the articles independently. Analysis was then conducted based on Apelin dose, route of administration, and follow-up. The findings were reported as standardized mean difference (SMD) with a 95% confidence interval (95% CI).
Results: Data from 10 animal studies were included in the present systematic review. Time interval between Apelin administration and blood pressure assessment was 1 to 21 minutes. Findings showed that administration of Apelin immediately reduces mean arterial pressure (MAP) (SMD=-3.13; 95% CI: -4.43 to -1.82; p<0.001), systolic blood pressure (SBP) (SMD= -1.62; 95% CI: -2.22 to -1.02; p<0.001), and diastolic blood pressure (DBP) (SMD= -1.10; 95% CI: -1.59 to -0.62; p<0.001). On follow-up, the effects of Apelin on MAP (meta-regression coefficient=-2.46; p=0.002) and DBP (meta-regression coefficient= -0.16; p=0.012) decreased over time, while the blood pressure lowering effects of Apelin on SBP did not change during follow-up (meta-regression coefficient=-0.17; p=0.063). It was also found that by increasing the dose of Apelin, DBP and SBP further reduced. These findings suggest that the effect of Apelin on SBP (meta-regression coefficient=0.08; p=0.001) and DBP (meta-regression coefficient=0.059; p=0.007) is dose-dependent, and their correlation is significant.
Conclusion: The present systematic review showed that peripheral administration of Apelin immediately reduces MAP, SBP and DBP in hypertensive animals. In contrast, central administration of Apelin increases these parameters.
- Hypertension
- Apelin
- Arterial Pressure
- Blood Pressure
##submission.howToCite##
参考
Ahmad KA, Yuan Yuan D, Nawaz W, Ze H, Zhuo CX, Talal B, et al. Antioxidant therapy for management of oxidative stress induced hypertension. Free radical research. 2017;51(4):428-38.
Egan BM, Kjeldsen SE, Grassi G, Esler M, Mancia G. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertens. 2019;37(6):1148-53.
Brito R, Castillo G, González J, Valls N, Rodrigo R. Oxidative stress in hypertension: mechanisms and therapeutic opportunities. Exp Clin Endocrinol Diabetes. 2015;123(6):325-35.
Korsager Larsen M, Matchkov VV. Hypertension and physical exercise: The role of oxidative stress. Medicina (Kaunas, Lithuania). 2016;52(1):19-27.
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nature Reviews Nephrology. 2020;16(4):223-37.
Massaro M, Scoditti E, Carluccio MA, De Caterina R. Oxidative stress and vascular stiffness in hypertension: A renewed interest for antioxidant therapies? Vascular pharmacology. 2019;116:45-50.
Horbal SR, Seffens W, Davis AR, Silvestrov N, Gibbons GH, Quarells RC, et al. Associations of Apelin, Visfatin, and Urinary 8-Isoprostane With Severe Hypertension in African Americans: The MH-GRID Study. American Journal of Hypertension. 2016;29(7):814-20.
Ma Y, Yue Y, Ma Y, Zhang Q, Zhou Q, Song Y, et al. Structural basis for apelin control of the human apelin receptor. Structure. 2017;25(6):858-66. e4.
Mughal A, O'Rourke ST. Vascular effects of apelin: Mechanisms and therapeutic potential. Pharmacol Ther. 2018;190:139-47.
Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y, et al. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res. 2007;101(4):e32-42.
Andersen CU, Hilberg O, Mellemkjær S, Nielsen-Kudsk JE, Simonsen U. Apelin and pulmonary hypertension. Pulmonary circulation. 2011;1(3):334-46.
Yamaleyeva LM, Brosnihan KB, Elsangeedy E, McGee C, Shi S, Caudell D, et al. Systemic Outcomes of (Pyr1)-Apelin-13 Infusion at Mid-Late Pregnancy in a Rat Model with Preeclamptic Features. Scientific Reports. 2019;9(1):8579.
Yamaleyeva LM, Chappell MC, Brosnihan KB, Anton L, Caudell DL, Shi S, et al. Downregulation of apelin in the human placental chorionic villi from preeclamptic pregnancies. Am J Physiol Endocrinol Metab. 2015;309(10):E852-60.
Inuzuka H, Nishizawa H, Inagaki A, Suzuki M, Ota S, Miyamura H, et al. Decreased expression of apelin in placentas from severe pre-eclampsia patients. Hypertension in pregnancy. 2013;32(4):410-21.
Wang C, Liu X, Kong D, Qin X, Li Y, Teng X, et al. Apelin as a novel drug for treating preeclampsia. Exp Ther Med. 2017;14(6):5917-23.
Andersen CU, Markvardsen LH, Hilberg O, Simonsen U. Pulmonary apelin levels and effects in rats with hypoxic pulmonary hypertension. Respir Med. 2009;103(11):1663-71.
Yamaleyeva LM, Shaltout HA, Varagic J. Apelin-13 in blood pressure regulation and cardiovascular disease. Current Opinion in Nephrology and Hypertension. 2016;25(5):396-403.
Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99(2-3):87-92.
Hooijmans CR, Rovers MM, de Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Medical Research Methodology. 2014;14(1):43.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315(7109):629-34.
Akcilar R, Turgut S, Caner V, Akcilar A, Ayada C, Elmas L, et al. Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats. Clinical and experimental hypertension. 2013;35(7):550-7.
Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem. 2004;279(25):26274-9.
Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O'Dowd BF. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology. 2005;146(1):231-6.
Rostamzadeh F, Najafipour H, Yeganeh-Hajahmadi M, Joukar S. Opioid receptors mediate inotropic and depressor effects of apelin in rats with 2K1C-induced chronic renovascular hypertension. Clinical and experimental pharmacology & physiology. 2018;45(2):187-97.
Siddiquee K, Hampton J, Khan S, Zadory D, Gleaves L, Vaughan DE, et al. Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. J Hypertens. 2011;29(4):724-31.
Soltani Hekmat A, Najafipour H, Nekooian AA, Esmaeli-Mahani S, Javanmardi K. Cardiovascular responses to apelin in two-kidney-one-clip hypertensive rats and its receptor expression in ischemic and non-ischemic kidneys. Regul Pept. 2011;172(1-3):62-8.
Yeganeh-Hajahmadi M, Najafipour H, Rostamzadeh F. The differential effects of low and high doses of apelin through opioid receptors on the blood pressure of rats with renovascular hypertension. Hypertension Research. 2017;40(8):732-7.
Zhao Y, Li Y, Li Z, Xu B, Chen P, Yang X. Superoxide anions modulate the performance of apelin in the paraventricular nucleus on sympathetic activity and blood pressure in spontaneously hypertensive rats. Peptides. 2019;121:170051.
Zhang F, Sun HJ, Xiong XQ, Chen Q, Li YH, Kang YM, et al. Apelin-13 and APJ in paraventricular nucleus contribute to hypertension via sympathetic activation and vasopressin release in spontaneously hypertensive rats. Acta physiologica (Oxford, England). 2014;212(1):17-27.
Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol. 2008;75(10):1882-92.
Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther. 2005;107(2):198-211.
Hashimoto T, Kihara M, Ishida J, Imai N, Yoshida S, Toya Y, et al. Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2006;26(6):1267-72.
Reaux-Le Goazigo A, Morinville A, Burlet A, Llorens-Cortes C, Beaudet A. Dehydration-induced cross-regulation of apelin and vasopressin immunoreactivity levels in magnocellular hypothalamic neurons. Endocrinology. 2004;145(9):4392-400.
Reaux A, Gallatz K, Palkovits M, Llorens-Cortes C. Distribution of apelin-synthesizing neurons in the adult rat brain. Neuroscience. 2002;113(3):653-62.
Yao F, Modgil A, Zhang Q, Pingili A, Singh N, O'Rourke ST, et al. Pressor Effect of Apelin-13 in the Rostral Ventrolateral Medulla: Role of NAD(P)H Oxidase-Derived Superoxide. Journal of Pharmacology and Experimental Therapeutics. 2011;336(2):372-80.
Salcedo A, Garijo J, Monge L, Fernandez N, Luis Garcia-Villalon A, Sanchez Turrion V, et al. Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanoids. Regul Pept. 2007;144(1-3):50-5.
- 摘要 ##plugins.themes.ojsPlusA.frontend.article.viewed##: 623 ##plugins.themes.ojsPlusA.frontend.article.times##
- pdf (English) ##plugins.themes.ojsPlusA.frontend.article.downloaded##: 346 ##plugins.themes.ojsPlusA.frontend.article.times##
##plugins.themes.ojsPlusA.frontend.article.downloadstatastics##
##plugins.block.makeSubmission.linkLabel##
SJR
COPE
